4D Molecular Therapeutics, Inc. (FDMT)
Largest Insider Buys in Sector
FDMT Stock Price History Chart
FDMT Stock Performance
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which …
Insider Activity of 4D Molecular Therapeutics, Inc.
Over the last 12 months, insiders at 4D Molecular Therapeutics, Inc. have bought $0 and sold $16.91M worth of 4D Molecular Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at 4D Molecular Therapeutics, Inc. have bought $44.27M and sold $7.83M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 850,000 shares for transaction amount of $13.6M was made by VIKING GLOBAL INVESTORS LP (10 percent owner) on 2023‑05‑09.
List of Insider Buy and Sell Transactions, 4D Molecular Therapeutics, Inc.
| 2024-09-16 | Sale | Chief Legal Officer | 500 0.001% | $16.33 | $8,165 | -44.36% | ||
| 2024-08-19 | Sale | Chief Legal Officer | 500 0.001% | $15.00 | $7,500 | -21.07% | ||
| 2024-07-16 | Sale | Chief Legal Officer | 1,750 0.0044% | $27.11 | $47,443 | -44.90% | ||
| 2024-07-11 | Sale | Chief Legal Officer | 1,996 0.0046% | $25.00 | $49,900 | 0.00% | ||
| 2024-07-10 | Sale | Chief Executive Officer | 12,923 0.0268% | $22.49 | $290,598 | 0.00% | ||
| 2024-07-01 | Sale | Chief Legal Officer | 4,248 0.0084% | $21.36 | $90,758 | 0.00% | ||
| 2024-06-24 | Sale | Chief Executive Officer | 12,930 0.0248% | $23.10 | $298,711 | -36.00% | ||
| 2024-06-17 | Sale | Chief Legal Officer | 1,750 0.0034% | $23.71 | $41,494 | -36.95% | ||
| 2024-05-16 | Sale | Chief Legal Officer | 1,750 0.0034% | $25.45 | $44,541 | -39.51% | ||
| 2024-04-16 | Sale | Chief Legal Officer | 1,750 0.0034% | $25.74 | $45,045 | -36.20% | ||
| 2024-04-01 | Sale | Chief Legal Officer | 8,153 0.0173% | $31.78 | $259,102 | -34.14% | ||
| 2024-03-27 | Sale | Chief Legal Officer | 5,833 0.0114% | $35.04 | $204,410 | -40.05% | ||
| 2024-03-18 | Sale | Chief Legal Officer | 1,750 0.0035% | $31.27 | $54,723 | -27.14% | ||
| 2024-02-27 | Sale | Chief Legal Officer | 1,909 0.0039% | $30.00 | $57,270 | -21.33% | ||
| 2024-02-16 | Sale | Chief Legal Officer | 1,750 0.0036% | $27.67 | $48,423 | -12.22% | ||
| 2024-02-08 | Sale | Chief Executive Officer | 92,001 0.3275% | $27.13 | $2.5M | -10.52% | ||
| 2024-02-08 | Sale | Chief Legal Officer | 1,996 0.0072% | $27.50 | $54,890 | -10.52% | ||
| 2024-02-05 | Sale | Chief Medical Officer | 6,552 0.0258% | $30.05 | $196,888 | -24.82% | ||
| 2024-01-23 | Sale | Chief Executive Officer | 5,696 0.0133% | $18.41 | $104,851 | +29.78% | ||
| 2024-01-05 | Sale | Chief Executive Officer | 28,237 0.0659% | $19.57 | $552,478 | +18.42% |
Insider Historical Profitability
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 4247914 8.1738% | $8.35 | 2 | 1 | <0.0001% |
| YAO TONY DUNG LING | director | 1060880 2.0413% | $8.35 | 1 | 0 | <0.0001% |
| MILLIGAN JOHN F | director | 100000 0.1924% | $8.35 | 1 | 0 | <0.0001% |
| Kamal Fariborz | See Remarks | 4347 0.0084% | $8.35 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $160.94M | 9.77 | 5.05M | +21.34% | +$28.3M | 0.16 | |
| Vr Adviser Llc | $140.18M | 8.51 | 4.4M | +28.5% | +$31.09M | 6.81 | |
| BlackRock | $136.51M | 8.29 | 4.28M | +23.67% | +$26.12M | <0.01 | |
| Bvf Inc Il | $124.97M | 7.59 | 3.92M | -2.12% | -$2.71M | 0.92 | |
| Janus Henderson | $101.84M | 6.18 | 3.2M | +3.37% | +$3.32M | 0.05 |